Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

Phase 2

Terminated

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: PEGPH20

First Posted Date: 2019-06-07

Last Posted Date: 2020-12-23

Lead Sponsor: Gulam Manji

Target Recruit Count: 1

Registration Number: NCT03979066

Locations: 🇺🇸
Columbia University, New York, New York, United States

Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2019-06-06

Last Posted Date: 2024-03-01

Lead Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Target Recruit Count: 43

Registration Number: NCT03976518

Locations: 🇮🇹
UOC di Oncologia Medica - Azienda Ospedaliero Universitaria di Parma, Parma, Italy
🇮🇹
UO di Oncologia Medica - Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna, Italy
🇮🇹
UO Oncologia Polmonare - AOU S. Luigi Gonzaga, Orbassano, Torino, Italy

and more 7 locations

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Solid Tumor

Interventions: Drug: Atezolizumab
Other: Chemotherapy (Arm A Only)
Drug: Tiragolumab

First Posted Date: 2019-06-06

Last Posted Date: 2024-08-12

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 46

Registration Number: NCT03977467

Locations: 🇺🇸
Florida Cancer Specialists - East, West Palm Beach, Florida, United States
🇺🇸
Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

and more 4 locations

Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Phase 3

Active, not recruiting

Conditions: Non Small Cell Lung Cancer Metastatic

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Atezolizumab

First Posted Date: 2019-06-06

Last Posted Date: 2023-12-14

Lead Sponsor: Intergroupe Francophone de Cancerologie Thoracique

Target Recruit Count: 500

Registration Number: NCT03977194

Locations: 🇫🇷
Bayonne - CH, Bayonne, France
🇫🇷
Avignon - Institut Sainte-Catherine, Avignon, France
🇫🇷
Metz - Thionville CHR, Ars-Laquenexy, France

and more 65 locations

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Phase 1

Withdrawn

Conditions: Select Advanced Solid Tumors

Interventions: Drug: IMC-C103C
Drug: Atezolizumab

First Posted Date: 2019-06-04

Last Posted Date: 2024-10-18

Lead Sponsor: Immunocore Ltd

Target Recruit Count: 75

Registration Number: NCT03973333

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
The University of Chicago Medicine & Biological Sciences, Chicago, Illinois, United States
🇺🇸
Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States

and more 15 locations

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Phase 1

Withdrawn

Conditions: Malignant Glioma

Interventions: Biological: PVSRIPO
Drug: Atezolizumab

First Posted Date: 2019-06-04

Last Posted Date: 2020-02-11

Lead Sponsor: Darell Bigner

Registration Number: NCT03973879

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Breast Cancer
Renal Cell Carcinoma

Interventions: Drug: IPI-549 (eganelisib)
Drug: Atezolizumab
Drug: nab-paclitaxel
Drug: Bevacizumab

First Posted Date: 2019-05-23

Last Posted Date: 2023-08-14

Lead Sponsor: Infinity Pharmaceuticals, Inc.

Target Recruit Count: 91

Registration Number: NCT03961698

Locations: 🇺🇸
Samsum Clinic, Santa Barbara, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
University Cancer & Blood Center, Athens, Georgia, United States

and more 21 locations

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Tesetaxel
Drug: Nivolumab
Drug: Atezolizumab
Drug: Pembrolizumab

First Posted Date: 2019-05-16

Last Posted Date: 2021-07-30

Lead Sponsor: Odonate Therapeutics, Inc.

Target Recruit Count: 294

Registration Number: NCT03952325

Locations: 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
🇸🇬
National Cancer Centre Singapore, Singapore, Singapore
🇺🇸
Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States

and more 8 locations

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck
Anal Canal Cancer
Cervical Cancer

Interventions: Biological: Blood sample collection
Procedure: Tumor biopsies
Other: CT scan
Drug: Atezolizumab
Drug: UCPVax

First Posted Date: 2019-05-10

Last Posted Date: 2024-12-20

Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Target Recruit Count: 47

Registration Number: NCT03946358

Locations: 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
CHU de Besançon, Besançon, France
🇫🇷
Centre Georges François Leclerc, Dijon, France

and more 1 locations

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Atezolizumab
Drug: Hu5F9-G4

First Posted Date: 2019-04-22

Last Posted Date: 2022-02-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 13

Registration Number: NCT03922477

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Yale, New Haven, Connecticut, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy